And still they keep coming – here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…
Four years ago, old high-school buddies Nicholas Quinn and Jesse Moors were taking in the sunshine at a café on Melbourne’s Southbank, when they decided to take their mutual interest in stock market investment to the next level. Quinn, a former PwC global tax specialist, and Moors, formerly a business development manager at CPA Australia,…
Shareholders of Link Administration Holdings (LNK), which provides services to the funds management and superannuation sectors and runs the share registry for many of the S&P/ASX 200 companies, have become the latest group to experience the tailwind that a takeover offer can suddenly blow on to a becalmed share price. Last weekend, a consortium of…
Big Australian Wins Battle of the Bulks OK, so you want to own a big global diversified bulk miner, to take advantage of the impending commodities boom – let’s take a look at the contenders, BHP and Rio Tinto. Here’s the tale of the tape. BHP (BHP, $36.35)Market capitalisation: $183.7 billionOne-year total return: +6.9%Three-year total…
Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…
Like everyone, Eben Bowditch, head of sales at Invesco Australia, was trying to navigate the abnormal and difficult times of the COVID-19 pandemic and wondering about the wellbeing of others. Was everyone feeling as disconnected as he was? Bowditch started to think about a way of creating stronger links among the financial services community. Other…
One of the great investment success stories of the last 25 years has been the exchange-traded fund (ETF), which got under way in the early 1990s as a vehicle offering access in one listed stock, to the entire stock market through tracking an index. Gone were the worries of paying “active” management fees and failing…
Another fintech is heading for the ASX screens, with online mortgage provider Lendi poised to push “go” on an initial public offering (IPO) that could see it list at a market capitalisation of between $500 million-$550 million. Lendi specialises in the home loan market: its software platform matches borrowers with more than 35 lenders. The…
4DMedical (4DX, $1.58)Market capitalisation: $418 millionThree-year total return: n/aAnalysts’ consensus target price: $1.70 (Thomson Reuters) Imaging company 4DMedical (4DX) surged on to the ASX screens in its August float, at a 100% “pop.” Issued in the prospectus at 73 cents, the shares opened for trade on August 7 at $1.47, and reached $1.70 in August…
It seems as if Japan does not get a lot of respect from external investors, for good reasons. The Nikkei index appears to disprove the theory that the sharemarket delivers superior long-term investment returns, being at the same level now that it was back in 1991. Almost 31 years on from its record high, the…
